Dorette S. Van Ingen Schenau

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL.

Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL.

Journal: HemaSphere
Published: October 28, 2025

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL.

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL.

Journal: Blood neoplasia
Published: May 06, 2024

Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy.

Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy.

Journal: Haematologica
Published: August 17, 2023

Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Journal: Cellular and molecular life sciences : CMLS
Published: May 29, 2023

Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways.

Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways.

Journal: Frontiers in oncology
Published: March 27, 2022

Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.

Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.

Journal: Haematologica
Published: September 07, 2021

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.

Journal: Blood
Published: March 19, 2021

The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.

The transcriptional repressor SNAI2 impairs neuroblastoma differentiation and inhibits response to retinoic acid therapy.

Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: April 25, 2019

Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.

Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.

Journal: Experimental hematology
Published: November 29, 2017

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Journal: Haematologica
Published: July 19, 2016

In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.

In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 23, 2016

Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.

Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.

Journal: Haematologica
Published: April 03, 2016
Showing 1-12 of 15

Last Updated: 09/26/2026